Nurix Therapeutics (NRIX) Capital Expenditures (2019 - 2026)

Nurix Therapeutics (NRIX) has 8 years of Capital Expenditures data on file, last reported at $1.0 million in Q1 2026.

• Capital Expenditures for Q1 2026 came in at $1.0 million, down 12.63% year-over-year; the trailing twelve-month figure through Feb 2026 was $13.9 million (up 82.61% YoY), and the FY2025 annual result was $14.0 million, up 51.0% from the prior year.
• Capital Expenditures retreated to $1.0 million in Q1 2026 per NRIX's latest filing, from $11.9 million in the prior quarter.
• Over five years, Capital Expenditures peaked at $11.9 million in Q4 2025 and troughed at -$5.2 million in Q4 2023.
• A 5-year average of $1.5 million and a median of $1.0 million in 2026 frame the typical range for Capital Expenditures.
• The sharpest annual moves came in 2022 and 2023: Capital Expenditures surged 896.72% in 2022, then plunged 1368.56% in 2023.
• A 5-year view of Capital Expenditures shows it stood at -$353000.0 in 2022, then sank by 1368.56% to -$5.2 million in 2023, then jumped by 140.61% to $2.1 million in 2024, then surged by 464.47% to $11.9 million in 2025, then tumbled by 91.21% to $1.0 million in 2026.
• Business Quant data shows NRIX's Capital Expenditures at $1.0 million in Q1 2026, $11.9 million in Q4 2025, and $1.0 million in Q3 2025.